Targeted bone marrow radiation tested for myeloma relapse – trial halted early
NCT ID NCT01794572
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a combination of high-dose chemotherapy (melphalan) and escalating doses of total bone marrow irradiation, followed by a stem cell rescue, in 13 people with multiple myeloma that had returned after initial treatment. The goal was to find the highest safe radiation dose. The trial was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Total bone marrow irradiation and melphalan chemotherapy
What this could lead to
If successful, this approach could offer a more targeted way to deliver high-dose therapy before a stem cell transplant for relapsed multiple myeloma.
What could go wrong
This was a very early, small trial that was terminated before completion. The combination of high-dose radiation and chemotherapy carries significant risks, including severe side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Claude Huriez, service d'hématologie
Lille, 59037, France
-
CHU Haut-Leveque, service d'Hématologie
Bordeaux, 33604, France
-
CHU Hautepierre, service d'hématologie
Strasbourg, 67098, France
-
CHU Hotel-Dieu, service d'hématologie
Nantes, 44093, France
-
CLCC Bergonie, service de radiotherapie
Bordeaux, 33076, France
-
CLCC ICO, service de radiothérapie
Saint-Herblain, 44805, France
-
CLCC Oscar Lambret, service de radiothérapie
Lille, 59020, France
-
CLCC Paul Strauss, service de radiothérapie
Strasbourg, 67091, France